Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status
Latin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission. Currently, several antiretroviral drugs, in various forms of administration, have demonstrated high efficacy and eff...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2025
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Enlace permanente (DOI o Handle) Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508859794685952 |
|---|---|
| author | Gonzales-Gavancho, Christian Araoz-Salinas, Julieta M. Tapia, Ruth Ramon Quispe‐Vicuña, Carlos Reategui-Garcia, Martín E. Rios-García, Wagner Baltodano-Calle, María J. Belanovic-Ramirez, Ivana Ortiz-Pardo, Allison N Ortiz-Saavedra, Brando Campos, Víctor Yosef Melt Alave Rosas, Jorge Luis Gonzales Zamora, Jose Armando |
| author_browse | Alave Rosas, Jorge Luis Araoz-Salinas, Julieta M. Baltodano-Calle, María J. Belanovic-Ramirez, Ivana Campos, Víctor Yosef Melt Gonzales Zamora, Jose Armando Gonzales-Gavancho, Christian Ortiz-Pardo, Allison N Ortiz-Saavedra, Brando Quispe‐Vicuña, Carlos Reategui-Garcia, Martín E. Rios-García, Wagner Tapia, Ruth Ramon |
| author_facet | Gonzales-Gavancho, Christian Araoz-Salinas, Julieta M. Tapia, Ruth Ramon Quispe‐Vicuña, Carlos Reategui-Garcia, Martín E. Rios-García, Wagner Baltodano-Calle, María J. Belanovic-Ramirez, Ivana Ortiz-Pardo, Allison N Ortiz-Saavedra, Brando Campos, Víctor Yosef Melt Alave Rosas, Jorge Luis Gonzales Zamora, Jose Armando |
| author_sort | Gonzales-Gavancho, Christian |
| collection | Producción científica |
| description | Latin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission. Currently, several antiretroviral drugs, in various forms of administration, have demonstrated high efficacy and effectiveness to protect against HIV. Among the oral drugs, we have emtricitabine/tenofovir and emtricitabine/tenofovir alafenamide, while alternative options include the dapivirine vaginal ring, injectable drugs such as Cabotegravir, and the most recently studied Lenacapavir. Despite their high efficacy and effectiveness, implementing PrEP in Latin America has been challenging throughout the region. Although some countries such as Brazil, Mexico, and Colombia have shown progress in increasing the number of users, there is a significant gap between these countries and others where PrEP access remains limited or non-existent. Barriers such as lack of awareness, inadequate funding, political instability, and outdated policies contribute to disparities in access, leaving many populations at high risk of HIV infection without this preventative measure. Innovative strategies need to be implemented to address and monitor policies that ensure access for all at-risk populations. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/150 |
| institution | UPeU |
| language | English |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/1502026-11-02T12:57:04ZUpdates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation StatusGonzales-Gavancho, ChristianAraoz-Salinas, Julieta M.Tapia, Ruth RamonQuispe‐Vicuña, CarlosReategui-Garcia, Martín E.Rios-García, WagnerBaltodano-Calle, María J.Belanovic-Ramirez, IvanaOrtiz-Pardo, Allison NOrtiz-Saavedra, BrandoCampos, Víctor Yosef MeltAlave Rosas, Jorge LuisGonzales Zamora, Jose ArmandoImplementationLatin AmericaHiv PreventionPre-exposure ProphylaxisLatin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission. Currently, several antiretroviral drugs, in various forms of administration, have demonstrated high efficacy and effectiveness to protect against HIV. Among the oral drugs, we have emtricitabine/tenofovir and emtricitabine/tenofovir alafenamide, while alternative options include the dapivirine vaginal ring, injectable drugs such as Cabotegravir, and the most recently studied Lenacapavir. Despite their high efficacy and effectiveness, implementing PrEP in Latin America has been challenging throughout the region. Although some countries such as Brazil, Mexico, and Colombia have shown progress in increasing the number of users, there is a significant gap between these countries and others where PrEP access remains limited or non-existent. Barriers such as lack of awareness, inadequate funding, political instability, and outdated policies contribute to disparities in access, leaving many populations at high risk of HIV infection without this preventative measure. Innovative strategies need to be implemented to address and monitor policies that ensure access for all at-risk populations.Articlehttps://pubmed.ncbi.nlm.nih.gov/40071257https://doi.org/10.53854/liim-3301-4PMC1189244710.53854/liim-3301-4https://hdl.handle.net/20.500.15037/15040071257W4408296921enInfezioni in Medicina1124-93902532-86892025-03-012026-06-13T07:48:22Z2026-06-13T07:48:22Z |
| spellingShingle | Implementation Latin America Hiv Prevention Pre-exposure Prophylaxis Gonzales-Gavancho, Christian Araoz-Salinas, Julieta M. Tapia, Ruth Ramon Quispe‐Vicuña, Carlos Reategui-Garcia, Martín E. Rios-García, Wagner Baltodano-Calle, María J. Belanovic-Ramirez, Ivana Ortiz-Pardo, Allison N Ortiz-Saavedra, Brando Campos, Víctor Yosef Melt Alave Rosas, Jorge Luis Gonzales Zamora, Jose Armando Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title_full | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title_fullStr | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title_full_unstemmed | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title_short | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status |
| title_sort | updates on hiv pre exposure prophylaxis in latin america available drugs and implementation status |
| topic | Implementation Latin America Hiv Prevention Pre-exposure Prophylaxis |
| topic_facet | Implementation Latin America Hiv Prevention Pre-exposure Prophylaxis |
| url | https://pubmed.ncbi.nlm.nih.gov/40071257 https://doi.org/10.53854/liim-3301-4 https://hdl.handle.net/20.500.15037/150 |
| work_keys_str_mv | AT gonzalesgavanchochristian updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT araozsalinasjulietam updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT tapiaruthramon updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT quispevicunacarlos updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT reateguigarciamartine updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT riosgarciawagner updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT baltodanocallemariaj updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT belanovicramirezivana updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT ortizpardoallisonn updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT ortizsaavedrabrando updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT camposvictoryosefmelt updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT alaverosasjorgeluis updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus AT gonzaleszamorajosearmando updatesonhivpreexposureprophylaxisinlatinamericaavailabledrugsandimplementationstatus |